Drug
Pozanicline clinical trials
Also written ABT-089.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
- ABT-089
- 11
Studies by the year they started
11 studies that test it; most in 2007 (4)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 11
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
AbbVie (prior sponsor, Abbott) (5) · Abbott (5) · University of Pennsylvania (1)
Studies
Open first, then newest update. How each study uses pozanicline is read from its arms, and is right about nine times in ten.
Testing it · 11
- Effects of ABT-089 on Smoking Abstinence Symptoms and RewardTerminatedPhase 2University of PennsylvaniaNCT01756053Written as ABT-089
- A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00528697Written as ABT-089
- Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00686933Written as ABT-089
- A Safety and Tolerability Study of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00443391Written as ABT-089
- Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00640419Written as ABT-089
- Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2AbbVie (prior sponsor, Abbott)NCT00640185Written as ABT-089
- A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)CompletedPhase 2AbbottNCT00391729Written as ABT-089
- A Study of the Long-term Safety of ABT-089 for Subjects With Mild-to-moderate Alzheimer's Disease Who Participated in the M06-876 StudyTerminatedPhase 2AbbottNCT00809510Written as ABT-089
- Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's DiseaseTerminatedPhase 2AbbottNCT00555204Written as ABT-089
- A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)TerminatedPhase 2AbbottNCT00554385Written as ABT-089
- A Study of the Safety and Efficacy of Multiple Doses of ABT-089 in Subjects With Alzheimer's DiseaseTerminatedPhase 2AbbottNCT00069849Written as ABT-089
Codes
What other systems call pozanicline · ClinicalTrials.gg INT004017
- MeSH (NLM) C108326pozaniclineOne source NLM
- UNII (FDA) CL2002R563POZANICLINEConfirmed FDA, NLM, Wikidata
- Wikidata Q14664566pozaniclineConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C81045PozaniclineOne source FDA
- DrugBank DB05458One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C108326 | pozanicline | One source NLM |
| UNII (FDA) | CL2002R563 | POZANICLINE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q14664566 | pozanicline | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C81045 | Pozanicline | One source FDA |
| DrugBank | DB05458 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.